Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein
- Bioactive
- What is this?
5
(1 Review)
|
(1 Publication)
Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein is a HIV-1 M:B_HXB2R Full Length protein, in the 36 to 507 aa range, expressed in HEK 293 cells, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, ELISA.
View Alternative Names
Envelope glycoprotein gp160, Env polyprotein, env
- ELISA
Supplier Data
ELISA - Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein (AB167715)
Immobilized ab167715 at 5 μg/mL (100 μL/well) can bind Recombinant human CD4 protein (Active) (ab167756) with a linear range of 1-39 ng/mL.
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein (AB167715)
SDS-PAGE of reduced ab167715 stained overnight with Coomassie Blue.
Reactivity data
Product details
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The HIV-1 gp120 protein facilitates viral attachment and entry into host cells. It forms a part of the gp160 precursor which cleaves into two subunits: gp120 and gp41 and together they create the HIV envelope spike complex. Gp120 specifically interacts with the CD4 receptor and subsequently co-receptors such as CCR5 or CXCR4 triggering fusion of the viral and cellular membranes through the gp41 protein.
Pathways
The HIV-1 gp120 protein initiates events critical to the human immunodeficiency virus infection process. It plays a role in the viral attachment and entry pathway which is necessary for HIV to penetrate host immune cells. Gp120's interaction with CD4 and co-receptors like CCR5 is essential for the establishment of infection integrating it into pathways involved in immune evasion and pathogenesis.
Specifications
Form
Lyophilized
General info
Function
Envelope glycoprotein gp160. Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.. Surface protein gp120. Attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Acts as a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells.. Transmembrane protein gp41. Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
Sequence similarities
Belongs to the HIV-1 env protein family.
Post-translational modifications
Palmitoylation of the transmembrane protein and of Env polyprotein (prior to its proteolytic cleavage) is essential for their association with host cell membrane lipid rafts. Palmitoylation is therefore required for envelope trafficking to classical lipid rafts, but not for viral replication.. Highly glycosylated by host. The high number of glycan on the protein is reffered to as 'glycan shield' because it contributes to hide protein sequence from adaptive immune system.. Specific enzymatic cleavages in vivo yield mature proteins. Envelope glycoproteins are synthesized as an inactive precursor that is heavily N-glycosylated and processed likely by host cell furin in the Golgi to yield the mature SU and TM proteins. The cleavage site between SU and TM requires the minimal sequence [KR]-X-[KR]-R. About 2 of the 9 disulfide bonds of gp41 are reduced by P4HB/PDI, following binding to CD4 receptor.
Subcellular localisation
Host endosome membrane
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in immunology 8:834 PubMed28824609
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com